Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium, quantity: 41.6 mg - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate; meglumine; titanium dioxide; indigo carmine aluminium lake; hypromellose; sunset yellow fcf aluminium lake; triacetin; allura red ac aluminium lake - rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,- prevention of cardiovascular events,rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,- in patients with hypercholesterolaemia,rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic s

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - cabazitaxel, quantity: 60 mg - injection, concentrated - excipient ingredients: polysorbate 80; citric acid - cabazitaxel dr.reddy?s in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - tadalafil, quantity: 20 mg - tablet - excipient ingredients: titanium dioxide; purified talc; hypromellose; magnesium stearate; poloxamer; sodium lauryl sulfate; triacetin; iron oxide yellow; croscarmellose sodium; microcrystalline cellulose; lactose - tadalafil-dr.reddy?s is indicated for the treatment of:,? erectile dysfunction (ed) in adult males.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - tadalafil, quantity: 5 mg - tablet - excipient ingredients: titanium dioxide; poloxamer; iron oxide yellow; microcrystalline cellulose; triacetin; magnesium stearate; sodium lauryl sulfate; croscarmellose sodium; hypromellose; lactose - tadalafil-dr.reddy's is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - tadalafil, quantity: 2.5 mg - tablet - excipient ingredients: lactose; hypromellose; triacetin; croscarmellose sodium; titanium dioxide; iron oxide yellow; magnesium stearate; microcrystalline cellulose; purified talc; poloxamer; sodium lauryl sulfate - tadalafil-dr.reddy's is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - tadalafil, quantity: 10 mg - tablet - excipient ingredients: magnesium stearate; triacetin; croscarmellose sodium; titanium dioxide; microcrystalline cellulose; iron oxide yellow; poloxamer; sodium lauryl sulfate; hypromellose; lactose; purified talc - tadalafil-dr.reddy?s is indicated for the treatment of:,? erectile dysfunction (ed) in adult males.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol - bortezomib-dr.reddy's (bortezomib 3.5 mg powder for injection), in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib-dr.reddy's (bortezomib 3.5 mg powder for injection), as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib-dr.reddy's (bortezomib 3.5 mg powder for injection) is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib-dr.reddy's (bortezomib 3.5 mg powder for injection) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - bortezomib 3.5mg (as a mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib - dr. reddy's, in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib - dr. reddy's as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib - dr. reddy's is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - tadalafil, quantity: 20 mg - tablet - excipient ingredients: titanium dioxide; purified talc; hypromellose; magnesium stearate; poloxamer; sodium lauryl sulfate; triacetin; iron oxide yellow; croscarmellose sodium; microcrystalline cellulose; lactose - tadalafil-dr.reddy?s is indicated for the treatment of:,? erectile dysfunction (ed) in adult males.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - tadalafil, quantity: 5 mg - tablet - excipient ingredients: titanium dioxide; poloxamer; iron oxide yellow; microcrystalline cellulose; triacetin; magnesium stearate; sodium lauryl sulfate; croscarmellose sodium; hypromellose; lactose - tadalafil-dr.reddy's is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males.